title: HIV infection, highly active antiretroviral therapy and the cardiovascular system.
abstract: Cardiovascular complications in the course of human immunodeficiency virus (HIV) infection are multifactorial and may be caused by the virus itself or by the related opportunistic infections and neoplasms. Highly active antiretroviral therapy (HAART) has prolonged many patients' lives, but many cardiac sequelae of HIV are not affected by HAART and continue to develop even with treatment. In addition, HAART itself causes in a high proportion of patients a metabolic syndrome, characterized by lipodystrophy/lipoatrophy, dyslipidemia and insulin resistance that may be associated with an increase in peripheral artery and coronary artery diseases. Careful cardiovascular evaluation in the course of HIV disease can identify cardiac complications early enough to treat. All HIV-infected patients candidate to antiretroviral therapy and patients already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk with the available guidelines.
authors.affiliation: Department of Medical Pathophysiology, University 'La Sapienza', Rome, Italy. g.barbaro@tin.it
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Barbaro
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001161:Arteriosclerosis / Q000139:chemically induced / Q000821:virology; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000821:virology; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000821:virology*; D003327:Coronary Disease / Q000209:etiology / Q000821:virology; D003331:Coronary Vessels / Q000821:virology; D004730:Endothelium, Vascular / Q000187:drug effects / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000821:virology; D016491:Peripheral Vascular Diseases / Q000139:chemically induced / Q000821:virology; D011480:Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D011480:Protease Inhibitors